BMYB34 Stock Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Bristol-Myers Squibb Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$355.25 |
| 52 Week High | US$363.51 |
| 52 Week Low | US$203.10 |
| Beta | 0.44 |
| 1 Month Change | 4.08% |
| 3 Month Change | 29.46% |
| 1 Year Change | 43.29% |
| 3 Year Change | -0.33% |
| 5 Year Change | 36.55% |
| Change since IPO | 439.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| BMYB34 | BR Pharmaceuticals | BR Market | |
|---|---|---|---|
| 7D | -1.6% | 4.3% | -0.8% |
| 1Y | 43.3% | -26.1% | -13.7% |
Return vs Industry: BMYB34 exceeded the BR Pharmaceuticals industry which returned -25.3% over the past year.
Return vs Market: BMYB34 exceeded the BR Market which returned -13% over the past year.
Price Volatility
| BMYB34 volatility | |
|---|---|
| BMYB34 Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in BR Market | 9.6% |
| 10% least volatile stocks in BR Market | 2.9% |
Stable Share Price: BMYB34 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: BMYB34's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1887 | 34,100 | Chris Boerner | www.bms.com |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Bristol-Myers Squibb Company Fundamentals Summary
| BMYB34 fundamental statistics | |
|---|---|
| Market cap | R$725.45b |
| Earnings (TTM) | -R$44.95b |
| Revenue (TTM) | R$293.75b |
2.5x
P/S Ratio-16.1x
P/E RatioIs BMYB34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMYB34 income statement (TTM) | |
|---|---|
| Revenue | US$47.44b |
| Cost of Revenue | US$11.44b |
| Gross Profit | US$35.99b |
| Other Expenses | US$43.25b |
| Earnings | -US$7.26b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | -3.58 |
| Gross Margin | 75.87% |
| Net Profit Margin | -15.30% |
| Debt/Equity Ratio | 289.5% |
How did BMYB34 perform over the long term?
See historical performance and comparisonDividends
4.3%
Current Dividend Yield-67%
Payout RatioDoes BMYB34 pay a reliable dividends?
See BMYB34 dividend history and benchmarks| Bristol-Myers Squibb dividend dates | |
|---|---|
| Ex Dividend Date | Jan 02 2025 |
| Dividend Pay Date | Feb 12 2025 |
| Days until Ex dividend | 8 days |
| Days until Dividend pay date | 49 days |
Does BMYB34 pay a reliable dividends?
See BMYB34 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 09:20 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bristol-Myers Squibb Company is covered by 51 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Charles Butler | Barclays |